Antagonists serotonin-dopamine

Atypical antipsychotic diugs Novel antipsychotic diugs serotonin/dopamine antagonists 5HT2A/D2 antagonists. 

Serotonin-dopamine antagonist and Gilles de la Tourette s syndrome an open pilot dose-tltratlon study with risperidone. Moi Disord 9 687-688. 

Carpenter WT Jr. Serotonin-dopamine antagonists and treatment of negative symptoms. J din Psychopharmacoi 1995 15(suppl 1) 30S-35S. 

Consistent with the role of both serotonin and dopamine in OCD, some OCD patients benefit from treatment with the new serotonin-dopamine antagonists (also known as atypical antipsychotics), especially when there is inadequate response to an SSRI. On the other hand, other patients have no therapeutic response to these new agents, and the condition of still others is even worsened by these drugs. The atypical antipsychotics and serotonin dopamine antagonism are discussed in Chapter 11. 

FIGURE 11-16. Serotonin-dopamine antagonist (SDA) icon. This icon represents the dual pharmacologic actions that define SDAs, namely blockade of serotonin 2A (5HT2A) receptors, as well as blockade of dopamine 2 (D2) receptors. 

What is an atypical antipsychotic From a pharmacological perspective, the atypical antipsychotics as a class may be defined in part as serotonin-dopamine antagonists (SDAs) (Fig. 11 — 16). Several other distinguishing pharmacological characteristics will be discussed in the following section. In this section, we will first discuss how the atypical antipsychotics all derive some of their atypical clinical properties from exploiting the different ways that serotonin and dopamine interact within the four key dopamine pathways in the brain. Thus, it is very important to understand serotonin-dopamine interactions in each of the four dopamine pathways. 

FIGURE 11-23. Here postsynaptic dopamine 2 receptors are being blocked by a serotonin-dopamine antagonist (SDA) atypical antipsychotic in the nigrostriatal dopamine pathway. This shows what would happen if only the dopamine 2 blocking action of an atypical antipsychotic were active— namely, the drug would only bind to postsynaptic D2 receptors and block them. However, see Figure 11-24. 

To discuss new drug discovery efforts in schizophrenia, including serotonin dopamine antagonists and other novel agents such as those based upon molecular and neurodevelopmental approaches to drug discovery. 

Which of the following serotonin dopamine antagonists (SDAs) is not considered to be a first line atypical antipsychotic drug ... 

The interaction between dopamine and serotonin in the nigrostriatal dopamine pathway may explain why serotonin dopamine antagonists have propensity for reducing extrapyramidal reactions. True or False. 

Has atypical antipsychotic properties (i.e., antipsychotic action without a high incidence of extrapyramidal symptoms), especially at low doses, but not a serotonin dopamine antagonist... 

Atypical antipsychotic (serotonin-dopamine antagonist second generation antipsychotic also a mood stabilizer)... 

Conventional antipsychotic (neuroleptic, dopamine 2 antagonist, serotonin dopamine antagonist)... 

Recently discovered to be a serotonin dopamine antagonist (binding studies and PET scans)... 

Active metabolites are also serotonin dopamine antagonists with longer half-lives than parent drug, thus possibly allowing once-daily treatment... 

No recognised classification system exists for atypical antipsychotics.Tentative terms based on receptor binding profiles have been applied to certain drug groupings.for example broad spectrum atypicals for clozapine, olanzapine and quetiapine. whilst risperidone and ziprasidone have been described as high affinity serotonin-dopamine antagonists . 

---